510(k) · Cleared
ClearedNasal Cease
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Catalina, Inc. · QSY Hemostatic Wound Dressing Without Thrombin Or Other Biologics
Cleared on Feb 2, 2011 as substantially equivalent to K070211 (Hemostasis, LLC, 2007) and 1 other predicate after a 133-day review. Its family tree reaches back 5 generations to 1982. 1 later device descends from it.
- Decided
- Feb 2, 2011
- Review
- 133 days
- Class
- Class U
- Product code
- QSY
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 5 generations to K821150 (1982). 24 ancestors in all. 1 later device descends from it, 1 citing it directly.
- Root · 5 generations backK821150 NU-Gauze SpongeJohnson & Johnson Professionals, Inc. · 1982
- 4 generations backK984069 Entaxis Nasal PackingLes Laboratorires Brothier, S.A. · 1999
- 3 generations backK993362 HylasineBiomatrix, Inc. · 2000
- 2 generations backK033666 HemadermMedafor, Inc. · 2003
- 1 generation backK070211 Traumarrest and Bleedarrest Hemostatic Particles and FoamHemostasis, LLC · 2007
- This deviceK102742 Nasal CeaseCatalina, Inc. · 2011
- Descendant · cites it directly · 0 of its ownK183622 NasalCEASE and BleedCEASELes Laboratoires Brothier S.A. · 2019
Most influential descendants
Showing 1 of 1 · See all- K183622NasalCEASE and BleedCEASELes Laboratoires Brothier S.A. · 2019 · cites it directly0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −5 | K821150 | NU-Gauze Sponge | Johnson & Johnson Professionals, Inc. | 1982 | — |
| −4 | K984069 | Entaxis Nasal Packing | Les Laboratorires Brothier, S.A. | 1999 | — |
| −3 | K993362 | Hylasine | Biomatrix, Inc. | 2000 | — |
| −2 | K033666 | Hemaderm | Medafor, Inc. | 2003 | — |
| −1 | K070211 | Traumarrest and Bleedarrest Hemostatic Particles and Foam | Hemostasis, LLC | 2007 | — |
| 0 (this device) | K102742 | Nasal Cease | Catalina, Inc. | 2011 | — |
| +1 | K183622 | NasalCEASE and BleedCEASE | Les Laboratoires Brothier S.A. | 2019 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1983 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1997 | 4 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 2 | 0 |
| 2001 | 3 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 1 | 0 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2019 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in QSY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new QSY device
- #1 K240713 Traumagel®score 15.0 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K070211 | Traumarrest and Bleedarrest Hemostatic Particles and FoamSummary page 5…d, drug Regulatory Class: Unclassified Product Code: FRO Trade Name: NasaICEASE® Substantially Equivalent to: BleedArrest® (K07021 1); NasalCEASE®(K04 1446) Description of the device: NasaICEASE® is comprised of calcium alginate and is manufactured as a sheet (… | 2007 |
| * | K041446 | NasalceaseSummary page 5…Regulatory Class: Unclassified Product Code: FRO Trade Name: NasaICEASE® Substantially Equivalent to: BleedArrest® (K07021 1); NasalCEASE®(K04 1446) Description of the device: NasaICEASE® is comprised of calcium alginate and is manufactured as a sheet (2x4x0.5 cm) of interwov… | 2004 |
What descends from it? (1)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K183622 | NasalCEASE and BleedCEASE | 2019 | 0 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 29 years and passes through 6 companies; a new generation was cleared every 3.8 years on median.
- None of the 24 ancestors has a recall.
- Of its descendants, K183622 (Les Laboratoires Brothier S.A., 2019) has gone furthest, with 0 descendants of its own.
- 4 other devices also cite its predicate K070211.
How does its category compare?
All QSY devicesQSY Hemostatic Wound Dressing Without Thrombin Or Other Biologics: FDA decisions, review times, recalls and adverse event reports over 20 years. 2011, this device’s year, is highlighted.
FDA decisions per year · QSY
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · QSY
142in 2024
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · QSY
No recall names QSY since 2007.
Adverse event reports per year · QSY
14in 2025
MAUDE reports naming product code QSY, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 13 | 63 | 0 | 0 |
| 2008 | 7 | 61 | 0 | 0 |
| 2009 | 9 | 55 | 0 | 0 |
| 2010 | 7 | 75 | 0 | 0 |
| 2011 | 8 | 137 | 0 | 0 |
| 2012 | 7 | 239 | 0 | 0 |
| 2013 | 3 | 161 | 0 | 0 |
| 2014 | 6 | 249 | 0 | 0 |
| 2015 | 6 | 171 | 0 | 0 |
| 2016 | 5 | 161 | 0 | 0 |
| 2017 | 1 | — | 0 | 0 |
| 2018 | 5 | 186 | 0 | 0 |
| 2019 | 4 | 336 | 0 | 0 |
| 2020 | 1 | — | 0 | 0 |
| 2021 | 1 | — | 0 | 0 |
| 2022 | 2 | — | 0 | 1 |
| 2023 | 7 | 586 | 0 | 0 |
| 2024 | 4 | 142 | 0 | 3 |
| 2025 | 2 | — | 0 | 14 |
| 2026 | 2 | — | 0 | — |
What is it indicated for?
This device has the following intended use.
NasalCEASE is intended to be used as a topical dressing for the local management of bleeding such as minor cuts, lacerations, and abrasions. NasalCEASE is already approved for treatment of minor nosebleeds.
It is intended to be marketed and sold as an Over-The-Counter device.
The device is not intended to be used for medium or severe wounds or bleeding.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K102742 · printed Nov 6, 2026
Cite this page
510(k) Report. “K102742: Nasal Cease.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K102742
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026